GEDiCube, a subsidiary of Renovaro focused on AI-powered cancer detection, has executed a binding Letter of Intent (LOI) to acquire a 75% stake in Dutch diagnostics company Cyclomics.
Both the parties have agreed to work on the drafting of a definitive agreement.
The combined company will advance the entry into the cancer monitoring market and gain access to integrating whole genome data into GEDiCube’s AI-ML platform.
Cyclomics has developed CyclomicsSeq, a novel circulating tumour DNA (ctDNA) assay based on Oxford Nanopore sequencing, for monitoring early cancer recurrence.
Unlike other available ctDNA-based methods, CyclomicsSeq is said to ensure that even a single ctDNA molecule in the blood can be detected at very high accuracy.
The company’s Omni-Omic 4th generation technology is expected to disrupt the cancer diagnostics market and clinical practice.
It enables rapid, reliable, and ultra-sensitive early test results or cancer recurrence detection using next-generation whole genome sequencing.
Cyclomics has also developed CyclomicsSeq TP53, an in vitro diagnostic (IVD) kit that integrates an advanced sequencing methodology and analysis software for early detection.
It can be applied to other cancer types harbouring TP53, such as small-cell lung cancer, squamous cell lung cancer, and triple-negative breast cancer, among others.
Cyclomics co-founder Alessio Marcozzi said: “Our Omni-Omic technology was developed to help empower AI platforms and thereby transform non-invasive healthcare solutions to detect cancers and other diseases as early as possible.
“GEDiCube’s innovative deep learning algorithms have created robust multi-omics panels that perform remarkably well. Together, I believe we will change the field.”
GEDiCube is committed to the early detection of cancer and has developed AI-powered high-performing biomarker panels for 13 frequently occurring cancer types.
The company’s technology advances the development and validation of panels into diagnostic products through in-silico validation, saving development time and money.
The panels focused on early detection of cancer and its recurrence, prediction of response to therapy, and personalised treatment, all through liquid biopsy tests.
GEDiCube’s platform, dubbed The Cube, combines unique AI, ML technology and algorithms, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team.
The platform deploys next-generation AI running on NVIDIA’s latest chips and stacks genetic and protein expression on top of DNA mutation for accuracy in cancer detection.
GEDiCube is focused on developing advanced diagnostic and monitoring tests that use multi-omics, integrating data from each stage of genetic expression.
GEDiCube CEO Coenraad van Kalken said: “There is enormous power in applying AI to multiple omics data layers that can be detected from a vial of blood from every patient with cancer.
“I believe that integrating Cyclomics into GEDiCube will allow us to gain greater accuracy and widespread Omni-omic measurements through next-generation sequencing and enter the cancer monitoring market this year.”
